ArticleInternational journal of clinical and experimental pathology2019
A combination of tumor and molecular markers predicts a poor prognosis in lung adenocarcinoma.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- The Predictive Value of Monocarboxylate Transporter 4 (MCT4) on Lung Adenocarcinoma Patients Treated with PD-1 Inhibitors.Journal of inflammation research · 2024Article
- CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma.Cell death discovery · 2023Article
- AI/ML advances in non-small cell lung cancer biomarker discovery.Frontiers in oncology · 2023Review
- Predicting the Lung Adenocarcinoma and Its Biomarkers by Integrating Gene Expression and DNA Methylation Data.Frontiers in genetics · 2022Article
- Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhether patients with stage IA-IIA lung adenocarcinoma require conventional chemotherapy is still a controversy. An ideal metastasis risk prediction model in lung adenocarcinoma is valuable for determining the prognosis and giving timely, individualized treatment.
resultsAnalyzing the clinical cases of 153 lung adenocarcinoma patients using an χ
conclusionUsing both complementary methods, the predictive models illustrated that the combination of tumor markers and a key molecule to predict the prognosis of lung adenocarcinoma patients in early stages is valuable. The postoperative transfer rate of stage I patients can be effectively predicted by these complementary methods.
Indexed as
Identifiers
31933987PMC6947110W3007268447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.